C3L-00140
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 70.82546201
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- FATTY_ACID_METABOLISM+0.430
- MYC_TARGETS_V1+0.360
- BILE_ACID_METABOLISM+0.280
- MYC_TARGETS_V2+0.270
- ADIPOGENESIS+0.260
- PANCREAS_BETA_CELLS+0.260
- XENOBIOTIC_METABOLISM+0.210
- PEROXISOME+0.190
- PROTEIN_SECRETION+0.170
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- G2M_CHECKPOINT-0.540
- E2F_TARGETS-0.500
- MITOTIC_SPINDLE-0.450
- NOTCH_SIGNALING-0.450
- TGF_BETA_SIGNALING-0.430
- ANGIOGENESIS-0.400
- APICAL_JUNCTION-0.400
- APICAL_SURFACE-0.390
- HEDGEHOG_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.875 |
| 2 | SRR8518209 | — | C | 0.870 |
| 3 | TCGA-35-3615-01A-01R-0946-07 | — | cohortA2 | 0.868 |
| 4 | SRR1313092 | — | B | 0.868 |
| 5 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.850 |
| 6 | SRR4296114 | — | cohortA1 | 0.845 |
| 7 | TCGA-BH-A18S-01A-11R-A12D-07 | — | B | 0.837 |
| 8 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.837 |
| 9 | TCGA-TN-A7HJ-01A-12R-A34R-07 | — | — | 0.832 |
| 10 | s0095165 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |